Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNYNF,SNY) Monday announced the dosing of first patients in the Phase 3 trial Of Dupilumab, an investigational therapy, co-developed by both the companies. The product candidate is indicated for atopic dermatitis, asthma and chronic sinusitis with nasal polyposis.
The phase 3 study, also called LIBERTY AD CHRONOS, is a randomized, double-blind, placebo-controlled, multi-national study with the primary objective of showing the efficacy of dupilumab in adults with moderate to severe atopic dermatitis or AD when administered concomitantly with topical corticosteroids through 16 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News